A novel dopamine agonist for the transdermal treatment of Parkinson's disease

被引：77

作者：

Jenner, P ^{[1
]}

机构：

[1] Kings Coll London, GKT Sch Biomed Sci, NDRG, Neurodegenerat Dis Res Ctr, London SE1 1UL, England

来源：

NEUROLOGY | 2005年 / 65卷 / 02期

关键词：

D O I：

10.1212/WNL.65.2_suppl_1.S3

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Rotigotine is a non-ergot, enantio-selective, D3/D2/D1 dopamine (DA) agonist drug that is effective in classical models of Parkinson's disease (PD), including the reserpinised mouse, the 6-hydroxydopamine-lesioned rat, and the MPTP-treated primate. It is active after oral administration but shows high clearance and a relatively short duration of effect. However, rotigotine is also effective after transdermal application in 6-hydroxydopamine-lesioned rats and MPTP-treated monkeys, in both of which the duration of effect is markedly enhanced. The pharmacologic properties of rotigotine suggest that it has the characteristics necessary to form the basis of a transdermal treatment for the control of motor symptoms of PD.

引用

页码：S3 / S5

页数：3

共 25 条

[1] N,N-DISUBSTITUTED 2-AMINOTETRALINS ARE POTENT D-2 DOPAMINE RECEPTOR AGONISTS [J].

BEAULIEU, M ;

ITOH, Y ;

TEPPER, P ;

HORN, AS ;

KEBABIAN, JW .

EUROPEAN JOURNAL OF PHARMACOLOGY, 1984, 105 (1-2) :15-21

[2]

BELLUZZI JD, 1994, MOVEMENT DISORD, V9, P147, DOI 10.1002/mds.870090204

[3] N-0923, a novel soluble dopamine D2 agonist in the treatment of parkinsonism [J].

Calabrese, VP ;

Lloyd, KA ;

Brancazio, P ;

Cefali, E ;

Martin, P ;

Wall, J ;

Sica, D .

MOVEMENT DISORDERS, 1998, 13 (05) :768-774

[4]

COLEMAN RJ, 1989, DISORDERS MOVEMENT, P147

[5] TRANSDERMAL ADMINISTRATION OF THE DOPAMINE AGONIST N-0437 AND 7 ESTER PRODRUGS - COMPARISON WITH ORAL-ADMINISTRATION IN THE 6-OHDA TURNING MODEL [J].

DENDAAS, I ;

TEPPER, PG ;

ROLLEMA, H ;

HORN, AS .

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1990, 342 (06) :655-659

[6]

FAHN S, 2001, PARKINSONISM RELAT D, V7, pS55

[7] SUBCUTANEOUS APOMORPHINE IN THE TREATMENT OF PARKINSONS-DISEASE [J].

FRANKEL, JP ;

LEES, AJ ;

KEMPSTER, PA ;

STERN, GM .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1990, 53 (02) :96-101

[8] Transdermal dopaminergic D2 receptor agonist therapy in parkinson's disease with n-0923 TDS:: A double-blind, placebo-controlled study [J].

Hutton, JT ;

Metman, LV ;

Chase, TN ;

Juncos, JL ;

Koller, WC ;

Pahwa, R ;

LeWitt, PA ;

Samii, A ;

Tsui, JKC ;

Calne, DB ;

Waters, CH ;

Calabrese, VP ;

Bennett, JP ;

Barrett, R ;

Morris, JL .

MOVEMENT DISORDERS, 2001, 16 (03) :459-463

[9]

Jankovic J., 2002, Parkinson's Disease and Movement Disorders, V4, P116

[10] PHARMACOLOGICAL PROFILE OF NON-HYDROXYLATED AND ETHER DERIVATIVES OF THE POTENT D2-SELECTIVE AGONIST N-0437 [J].

JANSEN, JM ;

DENDAAS, I ;

ROLLEMA, H ;

SWART, PJ ;

TEPPER, PG ;

DEVRIES, JB ;

HORN, AS .

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1991, 343 (02) :134-142

← 1 2 3 →